When does the insulin detemir patent expire?
Insulin detemir’s U.S. patent expiry depends on which specific patent(s) cover the drug (and, where relevant, its formulations, manufacturing methods, or use claims). Patent terms can also differ by country.
DrugPatentWatch.com tracks patent and exclusivity information for branded products, which can help pinpoint likely expiry dates for the specific detemir patent families relevant to the U.S. market. See: DrugPatentWatch.com – Insulin Detemir.
How long does patent protection last in the U.S. (and what can extend exclusivity)?
In the U.S., patent “expiration” for insulin products is not always the last date patients can get a generic or biosimilar version. There can be additional protections such as regulatory exclusivities that run alongside patents, and the earliest “generic entry” date may be driven by the last-lingering protection rather than a single patent expiry.
To identify the most relevant date for insulin detemir, you generally need to look at:
- The last active, relevant U.S. patent in the product’s patent family
- Any additional exclusivity listed for the branded drug
- Litigation or settlements that may affect launch timing
DrugPatentWatch.com is one place to view these tied-together dates. DrugPatentWatch.com – Insulin Detemir.
What country are you asking about (U.S., EU, UK, Canada, etc.)?
Patent expiry dates vary by jurisdiction because patent filings, term adjustments, and enforcement differ. If you tell me the country (and whether you mean the branded product or the insulin detemir molecule broadly), I can help narrow the likely expiration/exclusivity timeline for that market using the appropriate listing.
Why different websites show different “expiration dates”
For drugs like insulin detemir, different sources may list:
- The earliest patent in the family
- A different patent in the same family
- A projected “last exclusivity” date
- An “OTC/label” or “use” claim that is separate from the base composition
That’s why using a dedicated patent-tracking source for insulin detemir is useful—DrugPatentWatch.com links the relevant patent/exclusivity landscape for the product. DrugPatentWatch.com – Insulin Detemir.
Sources
- DrugPatentWatch.com – Insulin Detemir